Prevalence, cardiac phenotype and outcomes of TTR variants in the UK Biobank Population

Back

HFA Premium Access

Prevalence, cardiac phenotype and outcomes of TTR variants in the UK Biobank Population

Session: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Topic: Epidemiology, Prognosis, Outcome

Speaker: Doctor N. Aung (London, GB)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Nay Aung

Queen Mary University of London, London (United Kingdom of Great Britain & Northern Ireland)

5 presentations

0 follower

6 more presentations in this session

International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction

Speaker: Doctor S. Yun Viladomat (Hospitalet De Llobregat, ES)

Age- and sex-related trends in transthyretin amyloid cardiomyopathy prevalence in older patients with unexplained hypertrophic cardiomyopathy

Speaker: Professor R. Barriales-Villa (Coruna, A, ES)

SGLT2 inhibitor treatment in patients with cardiac amyloidosis

Speaker: Doctor D. Lavall (Leipzig, DE)

Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis

Speaker: Doctor A. Ioannou (Greater London, GB)

Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction

Speaker: Miss A. Achten (Maastricht, NL)

Access the full session

Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Speakers: Doctor N. Aung, Doctor S. Yun Viladomat, Professor R. Barriales-Villa, Doctor D. Lavall, Doctor A. Ioannou...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources